Nonafact

RSS

Withdrawn

This medicine's authorisation has been withdrawn

human coagulation factor IX
MedicineHumanWithdrawn

Maltese is available via eTranslation, the European Commission's machine translation service.

Translate to Maltese | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 13 May 2019, the European Commission withdrew the marketing authorisation for Nonafact (human coagulation factor IX) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sanquin Plasma Products B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Nonafact was granted marketing authorisation in the EU on 3 July 2001 for treatment of haemophilia B. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2006. 

The European Public Assessment Report (EPAR) for Nonafact is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (724.48 KB - PDF)

Ara

español (ES) (631.1 KB - PDF)

Ara

čeština (CS) (1.28 MB - PDF)

Ara

dansk (DA) (1.17 MB - PDF)

Ara

Deutsch (DE) (1.17 MB - PDF)

Ara

eesti (ET) (630.08 KB - PDF)

Ara

ελληνικά (EL) (1.32 MB - PDF)

Ara

français (FR) (632 KB - PDF)

Ara

hrvatski (HR) (651.68 KB - PDF)

Ara

italiano (IT) (630.99 KB - PDF)

Ara

latviešu (LV) (1.26 MB - PDF)

Ara

lietuvių (LT) (654.33 KB - PDF)

Ara

magyar (HU) (697.06 KB - PDF)

Ara

Malti (MT) (705.64 KB - PDF)

Ara

Nederlands (NL) (632.18 KB - PDF)

Ara

polski (PL) (677.25 KB - PDF)

Ara

português (PT) (630.8 KB - PDF)

Ara

română (RO) (652.2 KB - PDF)

Ara

slovenčina (SK) (702.68 KB - PDF)

Ara

slovenščina (SL) (696.3 KB - PDF)

Ara

suomi (FI) (630.29 KB - PDF)

Ara

svenska (SV) (631.66 KB - PDF)

Ara

Product information

български (BG) (1.46 MB - PDF)

Ara

español (ES) (701.19 KB - PDF)

Ara

čeština (CS) (2.16 MB - PDF)

Ara

dansk (DA) (1.28 MB - PDF)

Ara

Deutsch (DE) (1.29 MB - PDF)

Ara

eesti (ET) (756.74 KB - PDF)

Ara

ελληνικά (EL) (2.52 MB - PDF)

Ara

français (FR) (722.23 KB - PDF)

Ara

hrvatski (HR) (917.01 KB - PDF)

Ara

italiano (IT) (701 KB - PDF)

Ara

latviešu (LV) (1.93 MB - PDF)

Ara

lietuvių (LT) (881.32 KB - PDF)

Ara

magyar (HU) (1.2 MB - PDF)

Ara

Malti (MT) (1.22 MB - PDF)

Ara

Nederlands (NL) (740.48 KB - PDF)

Ara

polski (PL) (1.26 MB - PDF)

Ara

português (PT) (723.26 KB - PDF)

Ara

română (RO) (883.77 KB - PDF)

Ara

slovenčina (SK) (1.23 MB - PDF)

Ara

slovenščina (SL) (1.19 MB - PDF)

Ara

suomi (FI) (705.99 KB - PDF)

Ara

svenska (SV) (718.96 KB - PDF)

Ara
Latest procedure affecting product information:IB/0062
24/11/2016
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (678.58 KB - PDF)

Ara

español (ES) (658.5 KB - PDF)

Ara

čeština (CS) (665.25 KB - PDF)

Ara

dansk (DA) (663.15 KB - PDF)

Ara

Deutsch (DE) (665.66 KB - PDF)

Ara

eesti (ET) (625.82 KB - PDF)

Ara

ελληνικά (EL) (692.11 KB - PDF)

Ara

français (FR) (657.87 KB - PDF)

Ara

italiano (IT) (657.42 KB - PDF)

Ara

latviešu (LV) (1.2 MB - PDF)

Ara

lietuvių (LT) (644.52 KB - PDF)

Ara

magyar (HU) (643.21 KB - PDF)

Ara

Malti (MT) (662.72 KB - PDF)

Ara

Nederlands (NL) (660.32 KB - PDF)

Ara

polski (PL) (665.83 KB - PDF)

Ara

português (PT) (658.44 KB - PDF)

Ara

română (RO) (647.42 KB - PDF)

Ara

slovenčina (SK) (663.13 KB - PDF)

Ara

slovenščina (SL) (649.75 KB - PDF)

Ara

suomi (FI) (658.13 KB - PDF)

Ara

svenska (SV) (661 KB - PDF)

Ara

Product details

Name of medicine
Nonafact
Active substance
human coagulation factor IX
International non-proprietary name (INN) or common name
human coagulation factor IX
Therapeutic area (MeSH)
Hemophilia B
Anatomical therapeutic chemical (ATC) code
B02BD04

Pharmacotherapeutic group

Antihemorrhagics

Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

Authorisation details

EMA product number
EMEA/H/C/000348
Marketing authorisation holder
Sanquin Plasma Products B.V.

Plesmanlaan 125
NL-1066 CX Amsterdam
The Netherlands

Marketing authorisation issued
03/07/2001
Revision
9

Assessment history

This page was last updated on

Share this page